Résumé
Purpose: To evaluate the short-term results of sub-tenon's injection of bevacizumab in patients with clinically significant macular edema [CSME]
Methods: In this prospective non comparative interventional case series, sub-tenon's injection of 2.5 mg/0.1 ml bevacizumab was performed for eyes with CSME. Macular thickness and best corrected visual acuity measurements were performed before and one month after injections
Results: Nineteen eyes of twelve patients with a mean age of 59.8 +/- 5.7 years were evaluated. Thirteen eyes [68.4%] had center-involving macular edema. No significant difference was observed between pre- and post-injection central subfield retinal thickness measurements [P = 0.3]. Central subfield thickness measurements improved or remained unchanged in 13 eyes [68.4%]. Baseline BCVA of 0.48 +/- 0.35 LogMAR improved to 0.36 +/- 0.26 LogMAR after injection [P = 0.01]. Improvement of >2 lines in BCVA was found in 5 eyes [26.3%], and no eye lost >2 lines of BCVA. No complication associated with sub-tenon's injection was observed
Conclusion: Sub-tenon's injection of bevacizumab resulted in significant short-term visual improvement in eyes with CSME. Retinal thickness changes were not significant